30
Participants
Start Date
October 1, 2020
Primary Completion Date
November 29, 2021
Study Completion Date
October 31, 2022
TACE combined with lenvatinib and sintilimab
Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Second Affiliated Hospital of Guangzhou Medical University
OTHER